Ado-trastuzumab Emtansine: A HER2-Positive Targeted Antibody-Drug Conjugate

Annals of Pharmacotherapy

Volumn 48, Issue 11, 2014, Pages 1484-1493

  Corrigan, Patricia A ^a   Cicci, Teresa A ^b   Auten, Jessica Johnston ^b   Lowe, Denise K ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b NONE

Author keywords

breast cancer; cancer; chemotherapy; drug development and approval; oncology

Indexed keywords

AMINOTRANSFERASE; ANTIBODY CONJUGATE; CAPECITABINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; LAPATINIB; TRASTUZUMAB; TRASTUZUMAB EMTANSINE; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; ERBB2 PROTEIN, HUMAN; FLUOROURACIL; MAYTANSINE; MONOCLONAL ANTIBODY; PERTUZUMAB; QUINAZOLINE DERIVATIVE; TAXOID;

ABDOMINAL PAIN; ANEMIA; BLEEDING; BONE DISEASE; BREAST CANCER; BREAST METASTASIS; CANCER GROWTH; CANCER PATIENT; CANCER PROGNOSIS; CARDIOTOXICITY; CELLULITIS; CONSTIPATION; DIARRHEA; DRUG EFFICACY; DRUG FATALITY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; EPISTAXIS; FATIGUE; GENE AMPLIFICATION; GENE OVEREXPRESSION; HEADACHE; HEART LEFT VENTRICLE FAILURE; HUMAN; HYPERBILIRUBINEMIA; HYPOKALEMIA; INFUSION RELATED REACTION; LEUKOPENIA; LIVER TOXICITY; LUNG EMBOLISM; LUNG HYPOPLASIA; MUSCULOSKELETAL PAIN; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMONIA; PROGRESSION FREE SURVIVAL; REVIEW; THROMBOCYTOPENIA; ANALOGS AND DERIVATIVES; BREAST NEOPLASMS; CLINICAL TRIAL (TOPIC); DISEASE FREE SURVIVAL; IMMUNOLOGY; METABOLISM; METASTASIS; MOLECULARLY TARGETED THERAPY; PATHOLOGY;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CLINICAL TRIALS AS TOPIC; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; FLUOROURACIL; HUMANS; IMMUNOCONJUGATES; MAYTANSINE; MOLECULAR TARGETED THERAPY; NEOPLASM METASTASIS; QUINAZOLINES; RECEPTOR, ERBB-2; TAXOIDS;

EID: 84908083983     PISSN: 10600280     EISSN: 15426270     Source Type: Journal    
DOI: 10.1177/1060028014545354     Document Type: Review

References (36)

1. Siegel R,Ma J,Zou Z,.Cancer Statistics, 2014.CA Cancer J Clin. 2014;64:9-29
2. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials.Lancet. 2005;365:1687-1717
3. Slamon DJ,Clark GM,Wong SG,.Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.Science. 1987;235:177-182
4. Dawood S,Broglio K,Buzdar AU,.Prognosis of women with MBC by HER2 status and trastuzumab treatment: an institutional-based review.J Clin Oncol. 2010;28:92-98
5. Slamon DJ,Leyland-Jones B,Shak S,.Use of chemotherapy plus a monoclonal antibody against Her2 for metastatic breast cancer that overexpresses Her2.N Engl J Med. 2001;344:783-792
6. Andersson M,Lidbrink E,Bjerre K,.Phase III randomized study comparing docetaxel plus trastuzumab with vinorelbine plus trastuzumab as first-line therapy of metastatic or locally advanced human epidermal growth factor receptor 2–positive breast cancer: the HERNATA study.J Clin Oncol. 2011;29:264-271
7. Schaller G,Fuchs I,Gonsch T,.Phase II study of capecitabine plus trastuzumab in human epidermal growth factor receptor 2 overexpressing metastatic breast cancer pretreated with anthracyclines or taxanes.J Clin Oncol. 2007;25:3246-3250
8. Baselga J,Cortés J,Kim SB,.Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer.N Engl J Med. 2012;366:109-119
9. Verma S,Miles D,Gianni L,.Trastuzumab emtansine for HER2-positive advanced breast cancer.N Engl J Med. 2012;367:1783-1791
10. Geyer CE,Forster J,Linquist D,.Lapatinib plus capecitabine for HER2-positive advanced breast cancer.N Engl J Med. 2006;355:2733-2743
11. Sassoon I,Blanc C.Antibody-drug conjugate (ADC) clinical pipeline: a review.Methods Mol Biol. 2013;1045:1-27
12. South San Francisco, CA: Genentech, Inc; 2013:
13. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology: Breast Cancer (V3.2014). http://www.nccn.org/professionals/physician_gls/pdf/breast.pdf. Accessed July 15, 2014.
14. Lewis Phillips GD,Li G,Dugger DL,.Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate.Cancer Res. 2008;68:9280-9290
15. Poon KA,Flagella K,Beyer J,.Preclinical safety profile of trastuzumab emtansine (T-DM1): mechanism of action of its cytotoxic component retained with improved tolerability.Toxicol Appl Pharmacol. 2013;273:298-313
16. Junttila TT,Li G,Parsons K,.Trastuzumab-DM1 (ado-trastuzumab emtansine) retains all mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer.Breast Cancer Res Treat. 2011;128:347-356
17. Hudis CA.Trastuzumab: mechanism of action and use in clinical practice.N Engl J Med. 2007;357:39-51
18. Valabrega G,Montemurro F,Aglietta M.Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer.Ann Oncol. 2007;18:977-984
19. Krop IE,Beeram M,Modi S,.Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive MBC.J Clin Oncol. 2010;28:2698-2704
20. Girish S,Gupta M,Wang B,.Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody-drug conjugate in development for the treatment of HER2-positive cancer.Cancer Chemother Pharmacol. 2012;69:1229-1240
21. Shen B-Q,Bumbaca D,Saad O,.Catabolic fate and pharmacokinetic characterization of trastuzumab emtansine (T-DM1): an emphasis on preclinical and clinical catabolism.Curr Drug Metab. 2012;13:901-910
22. Lu D,Joshi A,Wang B,.An integrated multiple-analyte pharmacokinetic model to characterize trastuzumab emtansine (T-DM1) clearance pathways and to evaluate reduced pharmacokinetic sampling in patients with HER2-positive MBC.Clin Pharmacokinet. 2013;52:657-672
23. Burris H,Rugo H,Vukelja S,.Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy.J Clin Oncol. 2011;29:398-405
24. Krop I,LoRusso P,Miller K,.A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive MBC who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane and capecitabine.J Clin Oncol. 2012;30:3234-3241
25. Hurvitz A,Dirix L,Kocsis J,.Phase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive MBC.J Clin Oncol. 2013;31:1157-1163
26. Miller KD,Dieras V,Harbeck N,.Phase IIa trial of trastuzumab emtansine with pertuzumab for patients with human epidermal growth factor receptor 2-positive, locally advanced, or metastatic breast cancer 2014].J Clin Oncol.:
27. Krop IE,Kim SB,Gonzales-Martin A,.Trastuzumab emtansine versus treatment of physician’s choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomized, open-label, phase 3 trial.Lancet Oncol. 2014;15:689-699
28. South San Francisco, CA: Genentech; 2013:
29. Welslau M,Diéras V,Sohn JH,.Patient reported outcomes from EMILIA, a randomized phase 3 study of trastuzumab emtansine (T-DM1) versus capecitabine and lapatanib in human epidermal growth factor receptor 2-positive locally advanced or metastatic breast cancer.Cancer. 2014;120:642-651
30. US Department of Health and Human Services. Common terminology criteria for adverse events (CTCAE) (V4.03 2010). http://evs.nci.nih.gov/ftp1/CTCAE/About.html. Accessed June 3, 2014.
31. National Alert Network: Institute for Safe Medication Practices. Confusion regarding the generic name of the HER2-targeted drug KADCYLA (ado-trastuzumab emtansine). http://www.ismp.org/pressroom/20130417.pdf. Accessed February 1, 2014.
32. US Food and Drug Administration. Kadcyla (ado-trastuzumab emtansine): drug safety communication—potential medication errors resulting from name confusion. http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm350817.htm. Updated May6, 2013. Accessed March 24, 2013.
33. ClinicalTrials.gov. A service of the US National Institutes of Health: ado-trastuzumab. http://www.clinicaltrials.gov/ct2/results?term=ado-trastuzumab, Accessed February 16, 2014.
34. StantonT. Roche’s Perjeta proves a fast fave with cancer docs, but Kadcyla’s a speed racer. http://www.fierce-pharmamarketing.com/story/roches-perjeta-proves-fast-fave-cancer-docs-kadcylas-speed-racer/2014-03-19. Accessed Ma-rch 27, 2014.
35. Red Book Online [Internet database]. Greenwood Village, CO: Thomson Reuters (Healthcare) Inc; http://micromedex.com/redbook. Accessed April 1, 2014.
36. Kadcyla Web site. https://www.kadcyla.com/financial-assistance-programs. Accessed March 27, 2014.